March 21, 2021
1 min read
Source / information
Published by:
Disclosure:
Poppas does not report any relevant financial information.
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.
Back to Healio
The American College of Cardiology and Novo Nordisk announced that they have launched a program to improve multidisciplinary care for patients with type 2 diabetes.
The global UNITE (Multidisciplinary Teams in Cardiometabolic Care) program provides training and tools for clinicians in a variety of disciplines to enable an integrated approach to the treatment of type 2 diabetes and CVD. This emerges from a press release from the ACC.
Source: Adobe Stock
Athena Poppas
“Despite advances in care, people with type 2 diabetes continue to be at greater risk of death and disability from cardiovascular disease,” said ACC President Athena Poppas, MD, FACC, The director of the Lifespan Cardiovascular Institute in Providence, Rhode Island, chief of cardiology and professor of medicine at Brown University’s Warren Alpert School of Medicine said in the press release. “New strategies are needed to treat this complex disease. With UNITE, we meet this need by providing guidance and tools that can be easily integrated into daily clinical practice to optimize cardiovascular risk through treatment pathways and collaborative management of comorbidities. “
The program can help clinicians implement the ACC’s consensus decision-making path recommendations published in August on managing CV risk in type 2 diabetes.
The program will include cardiometabolic webinars, cardiometabolic education modules for those managing CV care, and a live cardiometabolic clinic, according to the press release.
In September, ACC and Novo Nordisk launched an initiative to help reduce the risk of CV in patients with type 2 diabetes.
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.
Back to Healio
